Summary of COVID-19 xiannuoxin studies

1. Wang et al., Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial

32 patient xiannuoxin early treatment RCT: 68% faster recovery (p=0.06) and 38% improved viral clearance (p=0.11).
RCT 32 adults with asymptomatic, mild or moderate COVID-19 in China showing greater viral load reduction and faster time to symptom alleviation with xuannuoxin (simnotrelvir plus ritonavir) compared to placebo. All adverse events were mild.
Sep 2023, The Lancet Regional Health - Western Pacific, https://www.sciencedirect.com/science/article/pii/S2666606523001530, https://c19p.org/wang23

2. Cao et al., Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19

1,007 patient xiannuoxin early treatment RCT: 17% faster recovery (p=0.003).
RCT 1,208 outpatients with mild-moderate COVID-19 in China, showing faster symptom resolution (by 35.8 hours) and faster viral clearance with xiannuoxin (simnotrelvir plus ritonavir) twice daily for 5 days.
Jan 2023, New England J. Medicine, http://www.nejm.org/doi/10.1056/NEJMoa2301425, https://c19p.org/cao3